1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,480 | 5,500 | 15:52 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg (MaaT013) in Acute Graft-versus-Host Disease | 327 | Business Wire | MaaT Pharma submitted today a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its product candidate MaaT013, under the registered brand name of Xervyteg
Xervyteghas... ► Artikel lesen | |
| 14.05. | MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress | 235 | Business Wire | Oral presentation will highlight updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013.
Poster presentation selected... ► Artikel lesen | |
| 14.05. | MaaT Pharma to Hold Annual General Meeting on June 20, 2025 | 236 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 13.05. | MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 | 248 | Business Wire | Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall... ► Artikel lesen | |
| 12.05. | MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) | 256 | Business Wire | Regulatory News:
MaaT Pharma(EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 29.04. | AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncology | - | pharmaphorum | ||
| 28.04. | MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 | 257 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 14.04. | Availability of MaaT Pharma's 2024 Universal Registration Document (URD) | 209 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| MAAT PHARMA Aktie jetzt für 0€ handeln | |||||
| 08.04. | MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT | 270 | Business Wire | Following a milestone unblinded interim safety review, the independent Data Safety Monitoring Board (DSMB) has recommended that the study proceed without modification. MaaT033, a pooled... ► Artikel lesen | |
| 07.04. | MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co | 415 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 04.04. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 324 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 31.03. | MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients' Responses to Immunotherapies | 285 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 27.03. | MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results | 822 | Business Wire | Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results (January 2025) showed a 62% gastrointestinal overall response rate at Day 28 and 1-year... ► Artikel lesen | |
| 19.03. | MaaT Pharma stock adds 7% on DSMB nod | 3 | Investing.com | ||
| 18.03. | MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease | 291 | Business Wire | The Independent Data Safety and Monitoring Board (DSMB) confirmed the remarkable efficacy results and a positive benefit/risk profile of MaaT013 in this patient population
The Company plans... ► Artikel lesen | |
| 11.03. | MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013 | 443 | Business Wire | Positive EMA Pediatric Committee opinion has cleared the investigation clinical plan to evaluate the safety and efficacy of MaaT013 in patients from 6 years old to less than 18 years old with... ► Artikel lesen | |
| 21.01. | MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT | 463 | Business Wire | The Independent Data Safety and Monitoring Board (DSMB) has recommended that the trial proceeds as planned without modification. Consistent good safety profile and tolerability for MaaT033... ► Artikel lesen | |
| 08.01. | MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease | 610 | Business Wire | The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of MaaT013 as third-line treatment of aGvHD... ► Artikel lesen | |
| 07.01. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 384 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 10.12.24 | MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting | 404 | Business Wire | MaaT Pharma to host a KOL webinar on December 17th, 2024, to discuss data and the unmet medical need in acute Graft-versus-Host Disease (aGvHD) Register here.
Sustained High Response Rates... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 6,998 | +5,81 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 0,906 | +3,07 % | Here's Why You Should Add PacBio Stock to Your Portfolio Now | ||
| CENTOGENE | 0,120 | 0,00 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 2,206 | +1,94 % | Atai Life Sciences: Big Deal | Fast genau vier Jahre nach dem Börsenstart am 18. Juni 2021 gibt es signifikante Veränderungen bei Atai Life Science: So schließt sich das auf die Behandlung psychischer Erkrankungen spezialisierte... ► Artikel lesen | |
| BIOMERIEUX | 121,60 | +1,25 % | BIOMERIEUX: bioMérieux launches cutting-edge equine infectious respiratory disease testing | ||
| CYCLACEL | 0,649 | +8,36 % | Cyclacel Pharmaceuticals, Inc.: Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement | KUALA LUMPUR, MALAYSIA, June 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company that develops innovative... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,108 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,965 | +4,32 % | XTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive Officer | Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL") announced... ► Artikel lesen | |
| GENUS | 23,200 | 0,00 % | Dividendenbekanntmachungen (04.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERICAN EXPRESS COMPANY US0258161092 0,82 USD 0,742 EUR BARCLAYS PLC GB0031348658 0,055 GBP EUR BRISTOL-MYERS SQUIBB COMPANY US1101221083 0... ► Artikel lesen | |
| ABIONYX PHARMA | 1,220 | +0,16 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX)
Market:... ► Artikel lesen | |
| ANAPTYSBIO | 18,900 | +2,16 % | AnaptysBio, Inc.: Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA | Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month? blinded treatment periodFavorable safety and tolerability, particularly... ► Artikel lesen | |
| MEIRAGTX | 4,820 | +0,42 % | MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease | - This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease - RMAT designation includes the benefits... ► Artikel lesen | |
| AKESO | 8,900 | 0,00 % | Akeso gains NMPA approval for cadonilimab to treat cervical cancer | ||
| ISOFOL MEDICAL | 0,090 | -2,81 % | Isofol Medical AB: Isofol Medical AB (publ) publishes Interim report, January - March 2025 | GOTHENBURG, Sweden, May 21, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January - March 2025 is now available on the company's... ► Artikel lesen | |
| DIAGONAL BIO | 0,000 | 0,00 % | Diagonal Bio AB: Diagonal Bio has been approved for delisting from Nasdaq First North Growth Market | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that Nasdaq has approved Diagonal Bio's application for delisting from Nasdaq First North Growth Market ("First North"). The... ► Artikel lesen |
MAAT PHARMA SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,61 % bei einem Aktienkurs von 5,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAAT PHARMA SA finden Sie auf Wallstreet Online.